Eli Lilly (LLY)

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

The stock looks unstoppable.

Microsoft flagged that services that require Multi-Factor Authentication may return gateway timeout errors for users in the U.S.

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the "personalized medicine" movement, the company is currently grappling with extreme stock volatility following a series of aggressive regulatory maneuvers and high-stakes litigation [...]

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing clinical data from its primary rival, Novo Nordisk (NYSE: NVO), which announced that its highly anticipated next-generation weight-loss drug,

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated Phase 3 trial results for its next-generation obesity treatment, CagriSema. The data from the REDEFINE 4 study revealed that the drug,

The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website.

Novo Nordisk investors get a second bite at the Ozempic apple.

Novo's next-gen drug CagriSema didn't match weight loss from Eli Lilly's Zepbound.

Viking stock has plenty of room to run.

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know.

Animal health company Elanco (NYSE:ELAN) will be reporting earnings this Tuesday before market open. Here’s what you need to know.

Even a great stock has a ceiling.

These two healthcare stocks are likely headed higher from their current prices.

Growth stock ETFs offer a catch-all way to buy the dip in top stocks.

Market gains have left some stocks trading at expensive levels.

But it's good news for Eli Lilly, too.

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.

Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive.

Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn's disease patients achieved 3-year steroid-free remission.